Therapy with immunoglobulin: applications for monoclonal antibodies

Journal of Infusion Nursing

Volumn 29, Issue 3 SUPPL., 2006, Pages

  Stowell, Christopher P ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ADALIMUMAB; ALEMTUZUMAB; ARCITUMOMAB TC 99M; BASILIXIMAB; BEVACIZUMAB; CALCINEURIN INHIBITOR; CAPROMAB PENDETIDE IN 111; CENTARA; CENTERA; CETUXIMAB; CYCLOPHOSPHAMIDE; DACLIZUMAB; DOXORUBICIN; EFALIZUMAB; ETANERCEPT; FANOLESOMAB TC 99M; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN; IMMURAID LL2; INFLIXIMAB; INOLIMOMAB; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; LEUCOTAC; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; NEUTROSEC; NONSTEROID ANTIINFLAMMATORY AGENT; NORASEPT; OKT 3; OMALIZUMAB; ONCOSCINT; PALIVIZUMAB; PANONREX; PEXELIZUMAB; PREDNISONE; PRILIXIMAB; RITUXIMAB; STEROID; TACROLIMUS; TOSITUMOMAB I 131; TRASTUZUMAB; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG; VELUMA; VOTUMUMAB; ZOLIMOMAB; ANTINEOPLASTIC AGENT; CAPROMAB PENDETIDE; DIAGNOSTIC AGENT; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ANKYLOSING SPONDYLITIS; ANTIBODY SPECIFICITY; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; B CELL LYMPHOMA; BLEEDING; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INHIBITION; CANCER THERAPY; CARDIAC GRAFT REJECTION; CARDIOPULMONARY BYPASS; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COLON CANCER; COLORECTAL CARCINOMA; CORONARY ARTERY OBSTRUCTION; CROHN DISEASE; CRYOGLOBULINEMIA; CYTOMEGALOVIRUS; CYTOTOXICITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SPECIFICITY; DRUG SYNTHESIS; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEAD AND NECK CANCER; HEART INFARCTION; HEMOLYTIC ANEMIA; HEPATITIS B VIRUS; HUMAN; HYBRID CELL; HYBRIDOMA; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOTHERAPY; INFECTION; KIDNEY ALLOGRAFT REJECTION; KIDNEY GRAFT REJECTION; LIVER GRAFT REJECTION; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NONHODGKIN LYMPHOMA; OVARY CARCINOMA; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROSTATE CANCER; PSORIASIS; RABIES; RECANALIZATION; RECOMBINANT DNA TECHNOLOGY; RECTUM CANCER; REVIEW; RHEUMATOID ARTHRITIS; SEPTIC SHOCK; SOLID TUMOR; T CELL LYMPHOMA; TRANSPLANTATION; UNSTABLE ANGINA PECTORIS; VARICELLA ZOSTER VIRUS; VERTEBROBASILAR INSUFFICIENCY; VIRUS INFECTION; BIOSYNTHESIS; IMMUNOLOGY; PATIENT SELECTION; SECRETION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; HYBRID CELLS; HYBRIDOMAS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; INDICATORS AND REAGENTS; PATIENT SELECTION;

EID: 33747611902     PISSN: 15331458     EISSN: None     Source Type: Journal    
DOI: 10.1097/00129804-200605001-00004     Document Type: Review

References (125)

1. Yu Z, Lennon V. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. New Engl J Med. 1999;340:227-228.
2. Chowdhury PA, Wu H. Tailor-made antibody therapies. Methods. 2005;36:11.
3. Roque AC, Lowe CR, Taipa MA. Antibodies and genetically engineered related molecules: production and purification. Biotechnol Prog. 2004;20:639-654.
4. Kipriyanov SM, Le Gall F. Generation and production of engineered antibodies. Mol Biotechnol. 2004;26:39-60.
5. Goldblatt F, Isenberg DA. New therapies for rheumatoid arthritis. Clin Exp Immunol. 2005;140(2):195-204.
6. Efthimiou P, Markenson JA. Role of biological agents in immune-mediated inflammatory diseases. South Med J. 2005;98(2):192-204.
7. Chatenoud L. Monoclonal antibody-based strategies in autoimmunity and transplantation. Methods Mol Med. 2005;109:297-328.
8. Taylor PC. Anti-tumor necrosis factor therapies. Curr Opin Rheumatol. 2001;13:164-169.
9. Keystone EC, Kavanaugh AF, Sharp JT, et al. Human anti-tumor necrosis factor monoclonal antibody in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004;50:1400-1411.
10. Abraham E, Anzueto A, Gutierrez G, et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. Lancet. 1998;351:929-933.
11. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of Etanercept, a recombinant tumor necrosis factor receptor: fc fusion protein in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340:253-259.
12. Haug CE, Colvin RB, Delmonico FL, et al. A phase I trial of immunosuppression with anti-ICAM-1 (CD54) mAb in renal allograft recipients. Transplantation. 1993;55:766-773.
13. Kavanaugh AF, Davis LS, Jain RI, Nichols LA, Norris SH, Lipsky PE. A phase I/II open label study of the safety and efficacy of an anti-ICAM-1 (intercellular adhesion molecule-1; CD54) monoclonal antibody in early rheumatoid arthritis. J Rheumatol. 1996;23:1338-1344.
14. Verrier ED, Shernan SK, Taylor KM, et al for the PRIMO-CABG Investigators. Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial. JAMA. 2004;291:2319-2327.
15. Shernan SK, Fitch JC, Nussmeier NA, et al for the Pexelizumab Study Investigators. Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass. Ann Thorac Surg. 2004;77:942-949.
16. Theroux P, Armstrong PW, Mahaffey KW, et al. Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial. Eur Heart J. 2005;26:1964-1970.
17. Granger CB, Mahaffey KW, Weaver WD, et al for the COMMA Investigators. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in myocardial infarction treated with angioplasty (COMMA) trial. Circulation. 2003;108:1184-1190.
18. Mahaffey KW, Granger CB, Nicolau JC, et al for the COMPLY Investigators. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. Circulation. 2003;108:1176-1183.
19. Lipsky PE, van der Heijde DM, St Clair EW, et al. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2000;343:1594-1602.
20. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41:1552-1563.
21. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002;359:1187-1193.
22. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology. 2004;126:402-413.
23. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350(9):876-885.
24. von Andrian UH, Engelhardt B. Alpha4 integrins as therapeutic targets in autoimmune disease. N Engl J Med. 2003;348:68-72.
25. Tubridy N, Behan PO, Capildeo R, et al for the UK Antegrn Study Group. The effect of anti-a4 integrin antibody on brain lesion activity in MS. Neurology. 1999;53:466-472.
26. Dalton CM, Miszkiel KA, Barker GJ, et al. Effect of natalizumab on conversion of gadolimium-enhancing lesions to T1 hypointense lesions on relapsing multiple sclerosis. J Neurol. 2004;251:407-413.
27. Miller DH, Khan OA, Sheremata WA, et al. International natalizumab multiple sclerosis trial group. N Engl J Med. 2003;348:15-23. Available at: http://www.fda.gov/cder/drug/advisory/natalizumab.htm. Accessed March 2, 2005.
28. Kahan BD, Rajagopalan PR, Hall M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody. Transplantation. 1999;67:276-284.
29. van Gelder T, Zietse R, Yzermans JN, Rischen-Vos J, Vaessen LM, Weimar W. Long-term follow-up after induction treatment with monoclonal anti-interleukin-2 receptor antibody (BT563) in kidney allograft recipients: a double-blind, placebo-controlled trial. Transplant Proc. 1996;28:3221-3222.
30. van Gelder T, Balk AH, Jonkman FA, et al. A randomized trial comparing safety and efficacy of OKT3 and a monoclonal anti-interleukin-2 receptor antibody (BT563) in the prevention of acute rejection after heart transplantation. Transplantation. 1996;62:51-55.
31. Langrehr JM, Nussler NC, Neumann U, et al. A prospective randomized trial comparing interleukin-2 receptor antibody versus antithymocyte globulin as part of a quadruple immunosuppressive induction therapy following orthotopic liver transplantation. Transplantation. 1997;63:1772-1781.
32. Carl S, Wiesel M, Daniel V, Dorsam J, Opelz G, Staehler G. Rescue therapy with interleukin-2 receptor antibody in high-risk kidney transplant patients: a 3-year follow-up study. Transplant Proc. 1997;29:320-322.
33. Iberer F, Tscheliessnigg KH, Freigassner M, et al. Clinical experience with a monoclonal interleukin-2 receptor antibody (BT 563) for rejection therapy after orthotopic heart transplantation. Transplant Proc. 1994;26:3237-3239.
34. Lebwohl M, Tyring SK, Hamilton TK, et al for the Efalizumab Study Group. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med. 2003;349:2004-2013.
35. Roitt IM. OKT3: immunology, production, purification, and pharmacokinetics. Clin Transplant. 1993;7:367-373.
36. DeMattos AM, Norman DJ. OKT3 for treatment of rejection in renal transplantation. Clin Transplant. 1993;7:374-381.
37. Renlund DG. OKT3 for induction of immunosuppression and treatment of rejection in cardiac allograft recipients. Clin Transplant. 1993;7:393-402.
38. Hockerstedt K. Treatment and prevention of liver allograft rejection with OKT3. Clin Transplant. 1993;7:403-413.
39. Meiser BM, Reiter C, Reichenspurner H, et al. Chimeric monoclonal CD4 antibody: a novel immunosuppressant for clinical heart transplantation. Transplantation. 1994;58:419-423.
40. Knox S, Hoppe RT, Maloney D, et al. Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody. Blood. 1996;87:893-899.
41. Henslee-Downey PJ, Parrish RS, MacDonald JS, et al. Combined in vitro and in vivo T lymphocyte depletion for the control of graft-versus-host disease following haploidentical marrow transplant. Transplantation. 1996;61:738-745.
42. Webster AC, Playford EG, Higgins G, Chapman JR, Craig JC. Interleukin-2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation. 2004;77:166-176.
43. Wilson C, Brook NR, Gok MA, et al. Evaluation of daclizumab to reduce delayed graft function in non-heart-beating renal transplantation: a prospective, randomized trial. Transplant Proc. 2005;37:1774-1775.
44. Kramer BK, Kruger B, Mack M, et al. Steroid withdrawal or steroid avoidance in renal transplant recipients: focus on tacrolimus-based immunosuppressive regimens Transplant Proc. 2005;37:1789-1791.
45. Rostaing L, Cantarovich D, Mourad G, et al for the CARMEN Study Group. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation. 2005;79:807-814.
46. Hershberger RE, Starling RC, Eisen HJ, et al. Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med. 2005;352:2705-2713.
47. Lehmann R, Weber M, Berthold P, et al. Successful simultaneous islet-kidney transplantation using a steroid-free immunosuppression: two-year follow-up. Am J Transplant. 2004;4:1117-1123.
48. Boillot O, Mayer DA, Boudjema K, et al. Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study. Liver Transplantation. 2005;11:61-67.
49. Flieger D, Renoth S, Beier I. Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines. Cell Immunol. 2000;204:55-63.
50. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B-cells by ligation of CD20 with monoclonal antibodies. Blood. 1998;91:1644-1652.
51. Maloney DG, Grillo-Lopez AJ, White CA. IDEC-C2B8 (rituximab) abti-CD20 monoclonal antibody therapy in patients with relapses low-grade non-Hodgkin's lymphoma. Blood. 1997;6:2188-2195.
52. Chambers SA, Isenberg D. Anti-B cell therapy (rituximab) in the treatment of autoimmune diseases. Lupus. 2005;14(3):210-214.
53. Stasi R, Pagnao A, Stipa E. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood. 2001;98;952-957.
54. Cooper N, Stasi R, Cunningham-Rundles S, et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol. 2004;125(2):232-239.
55. Braendstrup P, Bjerrum OW, Nielsen OJ, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am J Hematol. 2005;78:275-280.
56. Berentsen S, Ulvestad E, Gjertsen BT, et al. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood. 2004;103:2925-2928.
57. Gupta N, Kavuru S, Patel D, et al. Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia. 2002;16:2092-2095.
58. Zaja F, De Vita S, Mazzaro C, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood. 2003;101:3827-3834.
59. Wiestner A, Cho HJ, Asch AS, et al. Rituximab in the treatment of acquired factor VIII inhibitors. Blood. 2002;100:3426-3428.
60. Zheng X, Pallera AM, Goodnough LT, Sadler JE, Blinder MA. Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab. Ann Intern Med. 2003;138:105-108.
61. Kasamon YL, Nguyen TN, Chan JA, Nascimento AF. EBV-associated lymphoma and chronic inflammatory demyelinating polyneuropathy in an adult without overt immunodeficiency. Am J Hematol. 2002;69:289-293.
62. Gatto B. Monoclonal antibodies in cancer therapy. Curr Med Chem Anti-Cancer Agents. 2004;4:411-414.
63. Hinoda Y, Sasaki S, Ishida T, Imai K. Monoclonal antibodies as effective therapeutic agents for solid tumors. Cancer Sci. 2004;95:621-625.
64. Levene AP, Singh G, Palmieri C. Therapeutic monoclonal antibodies in oncology. J R Soc Med. 2005;98:146-152.
65. Riethmuller G, Schneider-Gadicke E, Schlimok G, et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet. 1994;343:1177-1183.
66. Fields AL, Keller AM, Schwartzberg L, et al. Edrecolomab (17-1A antibody) in combination with 5-fluorouracil based chemotherapy in the adjuvant treatment of stage III colon cancer: results of a randomised North American phase III study [abstract]. Proc Am Soc Clin Oncol. 2002;21:128a.
67. Punt CJ, Nagy A, Douillard JY, et al. Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet. 2002;360:671-677.
68. Berek JS, Taylor PT, Gordon A, et al. Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. Clin Oncol. 2004;22:3507-3516.
69. Bianchi G, Albanell J, Eiermann W, et al. Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer. Clin Cancer Res. 2003;9:5944-5951.
70. Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185 HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol. 1998;16:2659-2671.
71. Bicknell R. The realization of targeted antitumour therapy. Br J Cancer. 2005;92(Suppl 1): S2-S5.
72. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.J Clin Oncol. 2005;23:3502-3508.
73. Leonard JP, Coleman M, Ketas JC, et al. Erpatuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. Clin Cancer Res. 2004;10:5327-5334.
74. Postema EJ, Raemaekers JM, Oyen WJ, et al. Final results of a phase I radioimmunotherapy trial using (186) Re-epratuzumab for the treatment of patients with non-Hodgkin's lymphoma. Clin Cancer Res. 2003;9:3995S-4002S.
75. Juweid M, Sharkey RM, Markowitz A, et al. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody. Cancer Res. 1995;55:5899S-5907S.
76. Blend MJ, Hyun H, Kozloff M, et al. Improved staging of B-cell non-Hodgkin's lymphoma patients with 99mTc-labeled LL2 monoclonal antibody fragment. Cancer Res. 1995;55(Suppl):5764S-5770S.
77. Wiseman GA, Gordon LI, Multani PS, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood. 2002;99:4336-4342.
78. Wiseman GA, White CA, Sparks RB, et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin(TM) radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Crit Rev Oncol/Hematol. 2001;39:181-194.
79. Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005;352:441-449.
80. Wahl RL. Tositumomab and (131)I therapy in non-Hodgkin's lymphoma. J Nucl Med. 2005;46(S1)128S-140S.
81. Amadori S, Suciu S, Willemze R, et al for the EORTC leukemia group and the GIMEMA leukemia group. Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first-line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups. Haematologica. 2004;89:950-956.
82. Lundin J, Kimby E, Bjorkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2002;100:768-773.
83. Knechtle SJ, Fernandez LA, Pirsch JD, et al. Campath-1H in renal transplantation: the University of Wisconsin experience. Surgery. 2004;136:754-760.
84. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005;23:4117-4126.
85. Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol. 2005;23:1984-1992.
86. Kaplan LD, Lee JY, Ambinder RF, et al. Rituximab does not improve clinical outcome in a randomized phase III trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin's lymphoma: AIDS-malignancies consortium trial 010. Blood. 2005;106:1538-1543.
87. Leonard JP, Coleman M, Ketas J, et al. Combination antibody therapy with epratuzumab and rituximab in elapsed/refractory non-Hodgkin's lymphoma. J Clin Oncol. 2005;23:5044-5051.
88. Fink-Puches R, Wolf IH, Zalaudek I, Kerl H, Cerroni L. Treatment of primary cutaneous B-cell lymphoma with rituximab. J Am Acad Dermatol. 2005;52:847-853.
89. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4079-4088.
90. Treon SP, Hunter Z, Barnagan AR. CHOP plus rituximab therapy in Waldenstrom's macroglobulinemia. Clin Lymphoma. 2005;5:273-277.
91. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;35:337-345.
92. Robert F, Ezekiel MP, Spencer SA, et al. Phase I study of antiepidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol. 2001;19:3234-3243.
93. Chan AT, Hsu MM, Goh BC, et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol. 2005;23:3568-3576.
94. Xiong HQ, Rosenberg A, LoBuglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J Clin Oncol. 2004;22:2610-2616.
95. Matar P, Rojo F, Cassia R, Moreno-Bueno G, et al. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin Cancer Res. 2004;10:6487-6501.
96. Russeva MG, Adams GP. Radioimmunotherapy with engineered antibodies. Expert Opin Biol Ther. 2004;4(2):217-231.
97. Hughes K, Pinsky CM, Petrelli NJ, et al. Use of carcinoembryonic antigen radioimmunodetection and computed tomography for predicting the resectability of recurrent colorectal cancer. Ann Surg. 1997;226:621-631.
98. Patt YZ, Podoloff DA, Curley S, et al. 489-95Technetium 99m-labeled IMMU-4, a monoclonal antibody against carcinoembryonic antigen, for imaging of occult recurrent colorectal cancer in patients with rising serum carcinoembryonic antigen levels. J Clin Oncol. 1994;12:4293-4297.
99. Balaban EP, Walker BS, Cox JV, et al. Detection and staging of small cell lung carcinoma with a technetium-labeled monoclonal antibody: a comparison with standard staging methods. Clin Nucl Med. 1992;17:439-445.
100. Vansant JP, Johnson DH, O'Donnell DM, et al. Staging lung carcinoma with a Tc-99m labeled monoclonal antibody. Clin Nucl Med.1992;17:431-438.
101. McQuarrie SA, Baum RP, Niesen A, et al. Pharmacokinetics and radiation dosimetry of 99Tc(m)-labelled monoclonal antibody B43.13 in ovarian cancer patients. Nucl Med Comm. 1997;18:878-886.
102. Collier BD, Abdel-Nabi H, Doerr RJ, et al. Immunoscintigraphy performed with In-111-labeled CYT-103 in the management of colorectal cancer: comparison with CT. Radiology. 1992;185:179-186.
103. Doerr RJ, Abdel-Nabi H, Krag D, Mitchell E. Radiolabeled antibody imaging in the management of colorectal cancer: results of a multicenter clinical study. Ann Surg. 1991;214:118-124.
104. Serafini AN, Klein JL, Wolff BG, et al. Radioimmunoscintigraphy of recurrent, metastatic, or occult colorectal cancer with technetium 99m-labeled totally human monoclonal antibody 88BV59: results of pivotal, phase III multicenter studies. J Clin Oncol. 1998;16:1777-1787.
105. Baum RP, Niesen A, Hertel A, Adams S, Kojouharoff G, Goldenberg DM, Hor G. Initial clinical results with tachnetium-99m-labeled LL2 monoclonal antibody fragment in the radioimmunodetection of B-cell lymphomas. Cancer. 1994;73:896-899.
106. Becker WS, Behr TM, Cumme F, et al. 67Ga citrate versus 99mTc-labeled LL2-Fab' (anti-CD22) fragments in the staging of B-cell non-Hodgkin's lymphoma. Cancer Res. 1995;55(Suppl):5771S-5773S.
107. Burgers JK, Hinkle GH, Haseman MK. Monoclonal antibody imaging of recurrent and metastatic prostate cancer. Semin Urol. 1995;13:103-112.
108. Maguire RT, Pascucci VL, Maroli AN, Gulfo JV. Immunoscintigraphy in patients with colorectal, ovarian, and prostate cancer: results with site-specific immunoconjugates. Cancer. 1993;72(11 Suppl):3453-3462.
109. Wynant GE, Murphy GP, Horoszewicz JS, et al. Immunoscintigraphy of prostatic cancer: preliminary results with 111in-labeled monoclonal antibody 7E11-C5.3 (CYT-356). Prostate. 1991;18:229-241.
110. Raj GV, Partin AW, Polascik TJ. Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. Cancer. 2002;94:987-996.
111. Ponsky LE, Cherullo EE, Starkey R, Nelson D, Neumann D, Zippe CD. Evaluation of preoperative ProstaScint scans in the prediction of nodal disease. Prostate Cancer Prostatic Dis. 2002;5:132-135.
112. Bonn D. Rapid diagnosis of equivocal appendicitis. Molec Med Today. 1998;4(9):367.
113. Kipper SL. The role of radiolabeled leukocyte imaging in the management of acute appendicitis. Q J Nucl Med. 1999;43:83-92.
114. Schomig A, Mehilli J, Antoniucci D, et al. Beyond 12 hours Reperfusion AlternatiVe Evaluation (BRAVE-2) Trial Investigators: mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: a randomized controlled trial. JAMA. 2005;293:2865-2872.
115. Bellandi F, Maioli M, Leoncini M, Toso A, Dabizzi RP. Early abciximab administration in acute myocardial infarction treated with primary coronary intervention. Int J Cardiol. 2005;108:356-342.
116. De Luca G, Suryapranata H, Stone GW, et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA. 2005;293:1759-1765.
117. Eckert B, Koch C, Thomalla G, et al. Aggressive therapy with intravenous abciximab and intra-arterial rtPA and additional PTA/stenting improves clinical outcome in acute vertebrobasilar occlusion: combined local fibrinolysis and intravenous abciximab in acute vertebrobasilar stroke treatment (FAST): results of a multicenter study. Stroke. 2005;36:1160-1165.
118. Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics. 2001;108:E36.
119. Milgrom H, Fick RB Jr, Su JQ, et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. RhuMAb-E25 Study Group. N Engl J Med. 1999;341:1966-1973.
120. Everitt DE, Davis CB, Thompson K, et al. The pharmacokinetics, antigenicity, and fusion-inhibition activity of RSHZ19, a humanized monoclonal antibody to respiratory syncytial virus, in healthy volunteers. J Infect Dis. 1996;174:463-469.
121. Taylor G, Porter T, Tempest P, et al. Antirespiratory syncytial virus monoclonal antibodies show promise in the treatment and prophylaxis of viral disease. Biochem Soc Trans. 1995;23:1063-1067.
122. Grimaldi M, Gouyon B, Michaut F, Huet F, Gouyon JB, Burgundy Perinatal Network. Severe respiratory syncytial virus bronchiolitis: epidemiologic variations associated with the initiation of palivizumab in severely premature infants with bronchopulmonary dysplasia. Pediatr Infect Dis J. 2004;23:1081-1085.
123. Feltes TF, Cabalka AK, Meissner HC, et al for the Cardiac Synagis Study Group. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143:532-540.
124. Subramanian KN, Weisman LE, Rhodes T, et al for the MEDI-493 Study Group. Safety, tolerance, and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. Pediatr Infect Dis J. 1998;17:110-115.
125. Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J, IRIS Study Group. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants. Pediatr Infect Dis J. 2003;22:823-827.